The Herbert Irving Comprehensive Cancer Center (HICCC) was designated an NCI Cancer Center in 1972 and gained comprehensive status in 1979. The HICCC is a component of Columbia University Medical Center and associated with New York-Presbyterian Hospital (NYPH). During the period 2003-07, CUMC and NYPH have committed over $312.7 million for i) new research initiatives in basic, clinical and population science;ii) new and expanded facilities for laboratory research and clinical activities;iii) recruitment and program restructuring;iv) support of the Center's administrative office;and v) bridge funding to offset reduced NCI CCSG support. A new Director, Riccardo Dalla-Favera, MD, was appointed in 2005 and given: i) authority over new facilities, including the Irving Cancer Research Center (ICRC), a new 10-story building dedicated to cancer research, with state-of-the-art laboratories (100,000 square feet) and incremental clinical (30,000 square feet) space in the Herbert Irving Pavilion (HIP);ii) a broad-based recruitment plan, which has already attracted 8 new faculty members to the HICCC;and iii) restructuring and expansion of the shared resources. The Director has fully reshaped the senior leadership of the HICCC with appointments of a Deputy Director for Clinical Research and Associate Directors for Basic Research, Clinical Research, Population Science, Biomedical Informatics, Shared Resources and Administration. The programmatic structure of the HICCC has been reorganized to increase cancer focus and interdisciplinary collaboration, and now includes 216 members from 22 Departments and 6 Schools, assigned to two Basic Research programs (Cancer Signaling Networks and Cancer Genetics &Epigenetics), three Disease-Specific programs (Breast Cancer, Prostate Cancer, and Lymphoid Development &Malignancy), and two Population Science programs (Cancer Epidemiology and Prevention, Control &Disparities). The HICCC administers and supports a total of 12 Shared Resources, of which four have been recently created.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA013696-39S1
Application #
8518702
Study Section
Subcommittee G - Education (NCI)
Program Officer
Adjei, Brenda A
Project Start
1997-07-04
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
39
Fiscal Year
2012
Total Cost
$140,000
Indirect Cost
$52,500
Name
Columbia University (N.Y.)
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Sengillo, Jesse D; Lee, Winston; Bilancia, Colleen G et al. (2018) Phenotypic expansion and progression of SPATA7-associated retinitis pigmentosa. Doc Ophthalmol 136:125-133
Moayedi, Yalda; Duenas-Bianchi, Lucia F; Lumpkin, Ellen A (2018) Somatosensory innervation of the oral mucosa of adult and aging mice. Sci Rep 8:9975
Hopkins, Benjamin D; Pauli, Chantal; Du, Xing et al. (2018) Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature 560:499-503
Kroeger, Heike; Grimsey, Neil; Paxman, Ryan et al. (2018) The unfolded protein response regulator ATF6 promotes mesodermal differentiation. Sci Signal 11:
Jauregui, Ruben; Thomas, Amanda L; Liechty, Benjamin et al. (2018) SCAPER-associated nonsyndromic autosomal recessive retinitis pigmentosa. Am J Med Genet A :
Ghorpade, Devram S; Ozcan, Lale; Zheng, Ze et al. (2018) Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance. Nature 555:673-677
Bianchetti, E; Bates, S J; Carroll, S L et al. (2018) Usp9X Regulates Cell Death in Malignant Peripheral Nerve Sheath Tumors. Sci Rep 8:17390
Jauregui, Ruben; Park, Karen Sophia; Duong, Jimmy K et al. (2018) Quantitative Comparison of Near-infrared Versus Short-wave Autofluorescence Imaging in Monitoring Progression of Retinitis Pigmentosa. Am J Ophthalmol 194:120-125
Proto, Jonathan D; Doran, Amanda C; Subramanian, Manikandan et al. (2018) Hypercholesterolemia induces T cell expansion in humanized immune mice. J Clin Invest 128:2370-2375
Shang, Enyuan; Zhang, Yiru; Shu, Chang et al. (2018) Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems. Sci Rep 8:15383

Showing the most recent 10 out of 331 publications